UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster
In US, 7% of psoriasis patients are starting or switching drugs every month
The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.
